
The study evaluated the cost-effectiveness and return on investment of an enhanced-care strategy for heterozygous familial hypercholesterolemia (HeFH) in primary care in Australia. Using a multistate Markov model, the study estimated that the general practitioner-led program resulted in a gain of 870 years of life lived and 1033 quality-adjusted life years compared to standard of care over the lifetime horizon. The incremental cost-effectiveness ratio was AU$14,664/quality-adjusted life year gained from a healthcare perspective. The strategy was cost-saving, with a return on investment of AU$5.64 per dollar from a societal perspective. The study concluded that an enhanced general practitioner-led model of care for HeFH is likely to be cost-effective.
Like
Save
Share